Oral retinoids and plasma lipids

Jessica S. Lilley, Macrae F. Linton, Sergio Fazio

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Retinoids and rexinoids are prescribed for conditions ranging from acne vulgaris to hyperkeratosis to cutaneous T cell lymphoma. Dyslipidemia is a frequent consequence of the use of these drugs, with more than one-third of patients manifesting aberrations in triglyceride (TG) levels. The efficacy of retinoic acid derivatives is linked to their influence on lipid metabolism in the skin, which can impair systemic lipid trafficking and metabolism in some patients. Thus, baseline screening for preexisting dyslipidemia and regular follow-up lipid panels are mandated, especially when powerful agents such as bexarotene are used. Dietary modification, increased physical activity, and weight management are the cornerstones of initial management for mild hypertriglyceridemia, which is a contributor to cardiovascular risk. More severe impairments (fasting TG > 500 mg/dL) warrant pharmacologic interventions early on to reduce the risk of pancreatitis. Retinoic acid derivative action, lipid metabolism, and treatment of incident dyslipidemias are reviewed to empower prescribers in management of adverse lipid effects.

Original languageEnglish (US)
Pages (from-to)404-410
Number of pages7
JournalDermatologic Therapy
Volume26
Issue number5
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Retinoids
Dyslipidemias
Lipid Metabolism
Tretinoin
Lipids
Triglycerides
Diet Therapy
Cutaneous T-Cell Lymphoma
Hypertriglyceridemia
Acne Vulgaris
Pancreatitis
Fasting
Exercise
Weights and Measures
Skin
Pharmaceutical Preparations
Therapeutics

Keywords

  • drug-induced dyslipidemia
  • retinoid
  • rexinoid
  • secondary hypertriglyceridemia

ASJC Scopus subject areas

  • Dermatology

Cite this

Oral retinoids and plasma lipids. / Lilley, Jessica S.; Linton, Macrae F.; Fazio, Sergio.

In: Dermatologic Therapy, Vol. 26, No. 5, 09.2013, p. 404-410.

Research output: Contribution to journalArticle

Lilley, JS, Linton, MF & Fazio, S 2013, 'Oral retinoids and plasma lipids', Dermatologic Therapy, vol. 26, no. 5, pp. 404-410. https://doi.org/10.1111/dth.12085
Lilley, Jessica S. ; Linton, Macrae F. ; Fazio, Sergio. / Oral retinoids and plasma lipids. In: Dermatologic Therapy. 2013 ; Vol. 26, No. 5. pp. 404-410.
@article{bfcc54f3aadf40ef99baf7aa8fef1423,
title = "Oral retinoids and plasma lipids",
abstract = "Retinoids and rexinoids are prescribed for conditions ranging from acne vulgaris to hyperkeratosis to cutaneous T cell lymphoma. Dyslipidemia is a frequent consequence of the use of these drugs, with more than one-third of patients manifesting aberrations in triglyceride (TG) levels. The efficacy of retinoic acid derivatives is linked to their influence on lipid metabolism in the skin, which can impair systemic lipid trafficking and metabolism in some patients. Thus, baseline screening for preexisting dyslipidemia and regular follow-up lipid panels are mandated, especially when powerful agents such as bexarotene are used. Dietary modification, increased physical activity, and weight management are the cornerstones of initial management for mild hypertriglyceridemia, which is a contributor to cardiovascular risk. More severe impairments (fasting TG > 500 mg/dL) warrant pharmacologic interventions early on to reduce the risk of pancreatitis. Retinoic acid derivative action, lipid metabolism, and treatment of incident dyslipidemias are reviewed to empower prescribers in management of adverse lipid effects.",
keywords = "drug-induced dyslipidemia, retinoid, rexinoid, secondary hypertriglyceridemia",
author = "Lilley, {Jessica S.} and Linton, {Macrae F.} and Sergio Fazio",
year = "2013",
month = "9",
doi = "10.1111/dth.12085",
language = "English (US)",
volume = "26",
pages = "404--410",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Oral retinoids and plasma lipids

AU - Lilley, Jessica S.

AU - Linton, Macrae F.

AU - Fazio, Sergio

PY - 2013/9

Y1 - 2013/9

N2 - Retinoids and rexinoids are prescribed for conditions ranging from acne vulgaris to hyperkeratosis to cutaneous T cell lymphoma. Dyslipidemia is a frequent consequence of the use of these drugs, with more than one-third of patients manifesting aberrations in triglyceride (TG) levels. The efficacy of retinoic acid derivatives is linked to their influence on lipid metabolism in the skin, which can impair systemic lipid trafficking and metabolism in some patients. Thus, baseline screening for preexisting dyslipidemia and regular follow-up lipid panels are mandated, especially when powerful agents such as bexarotene are used. Dietary modification, increased physical activity, and weight management are the cornerstones of initial management for mild hypertriglyceridemia, which is a contributor to cardiovascular risk. More severe impairments (fasting TG > 500 mg/dL) warrant pharmacologic interventions early on to reduce the risk of pancreatitis. Retinoic acid derivative action, lipid metabolism, and treatment of incident dyslipidemias are reviewed to empower prescribers in management of adverse lipid effects.

AB - Retinoids and rexinoids are prescribed for conditions ranging from acne vulgaris to hyperkeratosis to cutaneous T cell lymphoma. Dyslipidemia is a frequent consequence of the use of these drugs, with more than one-third of patients manifesting aberrations in triglyceride (TG) levels. The efficacy of retinoic acid derivatives is linked to their influence on lipid metabolism in the skin, which can impair systemic lipid trafficking and metabolism in some patients. Thus, baseline screening for preexisting dyslipidemia and regular follow-up lipid panels are mandated, especially when powerful agents such as bexarotene are used. Dietary modification, increased physical activity, and weight management are the cornerstones of initial management for mild hypertriglyceridemia, which is a contributor to cardiovascular risk. More severe impairments (fasting TG > 500 mg/dL) warrant pharmacologic interventions early on to reduce the risk of pancreatitis. Retinoic acid derivative action, lipid metabolism, and treatment of incident dyslipidemias are reviewed to empower prescribers in management of adverse lipid effects.

KW - drug-induced dyslipidemia

KW - retinoid

KW - rexinoid

KW - secondary hypertriglyceridemia

UR - http://www.scopus.com/inward/record.url?scp=84885443299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885443299&partnerID=8YFLogxK

U2 - 10.1111/dth.12085

DO - 10.1111/dth.12085

M3 - Article

VL - 26

SP - 404

EP - 410

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 5

ER -